PubMed Health⌕ Search

Biomedical subjects

E Diernaes

Publications and source records attributed to E Diernaes.

14 recordsLinked to original sources
PubMed1990

[Delayed pushing and frequency of vacuum extraction in deliveries under lumbar epidural analgesia].

With the object of reducing the high of vacuum extraction in deliveries with lumbar epidural analgesia, we introduced "late pushing" in these deliveries in 1988. By this is understood that the parturient women is first encouraged to push when the orifice is completely dilated and the infant's head is visible at introitus. Before the "late pushing" was introduced, the frequency of vacuum extractions in deliveries with lumbar epidural analgesia was 44% of the vaginal deliveries. During the period of investigation, the frequency was 43%. Introduction of the "late pushing" thus did not result in any alteration (p greater than 0.4). Parturient women with lumbar epidural analgesia and slow progression of labour differed from the remainder of the parturient women with lumbar epidiral analgesia by significantly higher birth weights (4,000 g as compared with 3,400 g) and this may explain the increased frequency of vacuum extraction in this particular group of parturient women. The authors consider that lumbar epidural analgesia has the advantage that delivery is less painful for the mother without any simultaneous increased risk for the infant.

Analgesia, Epidural↗
PubMed1989

Does medical therapy cure female stress incontinence?

Forty-four consecutive female patients, who were scheduled for operation for genuine stress incontinence but instead treated pharmacologically with an alpha-agonist or placebo for 3-4.5 months, were evaluated after a median observation period of 30 months. Ten patients (23%) underwent colposuspension. Fourteen patients (32%) claimed to be continent or so much improved that further treatment was considered unnecessary by the patients themselves. Of the remaining 20 patients who still claimed to have stress incontinence, 11 (25%) preferred to resume the pharmacological treatment whereas 9 patients (20%) had not decided whether they wanted further treatment. These results suggest that some operations for stress incontinence may be avoided by introduction of a standard trial of medical therapy prior to intended surgical intervention.

2-Hydroxyphenethylamine↗
PubMed1989

Norfenefrine in the treatment of female urinary stress incontinence assessed by one-hour pad weighing test.

Thirty-three women with urinary stress incontinence were treated with the alpha-adrenoceptor-stimulating agent, norfenefrine (Nevadral Retard). Treatment was administered during 3-24 weeks at a daily dosage of 90 mg. Judged by a 1-hour pad weighing test, a significant effect could be demonstrated. With the exception of 1 case of allergic reaction and 1 case of recurrent vomiting, a simultaneously performed tolerability test revealed only minor side effects.

2-Hydroxyphenethylamine↗
PubMed1988

Norfenefrine in the treatment of female stress incontinence. A double-blind controlled trial.

Forty-four consecutive patients with genuine stress incontinence were treated with norfenefrine 15-30 mg t.i.d. in a 6-week, double-blind and parallel, placebo-controlled study. Subjectively, 52% were improved and 26% became continent during norfenefrine treatment. Objectively (stress test), 30% became continent and the maximum urethral closure pressure increased 10% which was statistically significant. These results, however, were not statistically different from those of placebo treatment. Simultaneously, subjective and objective improvement was seen more often in patients given norfenefrine compared to placebo (p less than 0.1). In patients with most severe incontinence according to urodynamic criteria the effect of norfenefrine was statistically significantly better than placebo. A low incidence of side effects was observed and no differences between norfenefrine and placebo were found. It is concluded that norfenefrine may be of value in the treatment of female stress incontinence.

2-Hydroxyphenethylamine↗
PubMed1983

Neoplasia in the vagina following hysterectomy for dysplasia or carcinoma in situ of the uterine cervix.

With a view to establishing some of the factors responsible for an increased risk of neoplasia in the vagina following primary hysterectomy for dysplasia or carcinoma in situ of the cervix, 63 surgical specimens from patients with subsequent neoplasia in the vagina have been compared with specimens from 40 patients without subsequent neoplasia. We found the frequency of neoplasia in the vagina to be greater when dysplasia or carcinoma in situ could be demonstrated in the vaginal margin. Neither the degree of endocervical glandular involvement, the number of mitoses, nor the inflammatory response of the connective tissue appeared to be significant in this respect. No significant connection was found between the severity of the preinvasive lesion of the cervix and the subsequent neoplasia in the vagina.

Adult↗